OABIOmniAb, Inc.
Services-Commercial Physical & Biological Research
- Revenue
- $19M
- 29% YoY
- Operating margin
- -369.5%
- 31% YoY
- EBITDA
- −$47M
- 7.3% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired85% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear29% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $35M | $59M | $34M | $26M | $19M | 29% |
| Operating income | −$36M | −$27M | −$69M | −$75M | −$69M | 7.4% |
| Net income | −$27M | −$22M | −$51M | −$62M | −$65M | 4.4% |
| Operating cash flow | −$6M | −$4M | $2M | −$40M | −$36M | 8.1% |
| Capex | $4M | $17M | $2M | $2M | $565K | 70% |
| Stock-based comp | $15M | $18M | $25M | $21M | $16M | 26% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
No pay-versus-performance disclosure yet.